一种合成ERR激动剂减轻了代谢综合征
Cyrielle Billon1, Emmalie Schoepke2, Amer Avdagic2
1Center for Clinical Pharmacology, St. Louis College of Pharmacy, Washington University School of Medicine, University of Health Sciences and Pharmacy, St. Louis, Missouri (C.B., A.A., B.E.); Department of Pharmacology & Physiology (E.S., A.C., A.A.B., J.K.W.) and Department of Chemistry (J.K.W.), Saint Louis University School of Medicine, St. Louis, Missouri; and University of Florida Genetics Institute, Gainesville, Florida (T.P.B.) cyrielle.billon@uhsp.edu burris.thomas@ufl.edu.
一种新型药物SLU-PP-332通过激活雌激素相关受体 (ERRs) 来模仿运动的益处. 这促进脂肪减轻,改善新陈代谢,为肥胖和代谢综合征提供潜在的治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
- 分子生物学分子生物学
背景情况:
- 运动提供了显著的健康益处,包括降低死亡风险.
- 药理学炼模仿剂正在研究治疗肥胖和代谢综合征等代谢障碍.
- 雌激素相关受体 (ERR) 是核受体,在调节能量代谢方面发挥作用.
研究的目的:
- 为了研究SLU-PP-332的疗效,它是雌激素相关受体 (ERR) α,β和gamma的激素,作为运动模拟剂.
- 评估SLU-PP-332对肥胖和代谢综合征的小鼠模型中的代谢参数的影响.
主要方法:
- 将SLU-PP-332给饮食诱导的肥胖小鼠和肥胖/肥胖小鼠.
- 评估各种代谢参数,包括能源消耗和脂肪酸氧化.
- 评估脂肪质量积累和胰岛素敏感性的变化.
主要成果:
- SLU-PP-332的使用复制了运动诱导的全身新陈代谢的改善.
- 主要发现包括增加的能源消耗和增强的脂肪酸氧化.
- 该化合物导致脂肪质量积累减少,并在代谢综合征模型中改善胰岛素敏感性.
结论:
- 用SLU-PP-332对雌激素相关受体 (ERR) 的药理活性显示了运动模拟性质.
- 在临床前模型中,SLU-PP-332有效降低肥胖,改善代谢综合征标志物.
- 针对ERR代表了对代谢疾病的有前途的治疗策略.
相关概念视频
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...


